It seems like buying interests are coming back to COVID-19 stocks.

As Barron’s reports: “According to a data tracker from the New York Times, the daily average number of new cases in China is up more than 450% over the past two weeks.”

The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.

Healthcare, commodities, and now Bitcoin?

China in an about face implemented policy easing measures, cutting reserve requirements and announcing a loosening of property finance. This was to get ahead of an Evergrande default along with rapidly deteriorating developer financing conditions.

Between the Amazon Cloud issues and the clouds gathering over the Ukraine border, it's getting harder to tell exactly what's happening to markets. Here are some insights into the international companies in our portfolio.

Parallels between the government's response to 9/11 and to COVID-19; COVID vaccine maker BioNTech appears in our top ten again.

The CDC approved a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older, some adults with underlying medical conditions, and some adults in high-risk working and institutional settings.

Pfizer Inc expects to apply for U.S. authorization of its COVID-19 vaccine for children aged six months and five years in November, the Financial Times reported.

How to limit the damage when something goes wrong. We can't always be right, which is why we hedge..

Biden's vaccine mandate is another tail wind for our top name Moderna.

BioNTech jumped on the news, but some worry the FDA might have been a bit hasty in giving full approval to the Pfizer-BioNTech vaccine.

The Food and Drug Administration is expected next week to grant full approval of Pfizer and BioNTech's COVID-19 vaccine. The FDA is expected to grant full approval on Monday, Aug. 23.

The push for booster shots should benefit two of our recent top names, BioNTech and Moderna.

In the coming days, there could be a significant level of volatility present in BioNTech's share price.

The head of metals strategy at a leading global precious metals firm weighs in. Plus, what was up on Monday.